Patents by Inventor Emmanuelle Vigne

Emmanuelle Vigne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7033826
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: April 25, 2006
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Publication number: 20060002893
    Abstract: Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.
    Type: Application
    Filed: January 20, 2005
    Publication date: January 5, 2006
    Inventors: Emmanuelle Vigne, Jean-Francois Dedieu, Martine Latta, Patrice Yeh, Michel Perricaudet
  • Patent number: 6911199
    Abstract: Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g., for gene therapy of cancers or cardiovascular conditions.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: June 28, 2005
    Assignee: Aventis Pharma S.A.
    Inventors: Emmanuelle Vigne, Jean-Francois Dedieu, Martine Latta, Patrice Yeh, Michel Perricaudet
  • Publication number: 20050069523
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: July 9, 2003
    Publication date: March 31, 2005
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frederic Revah, Emmanuelle Vigne
  • Publication number: 20040224409
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for brain-derived neurotrophic factor (BDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: December 23, 2003
    Publication date: November 11, 2004
    Inventors: Laurent Pradier, Pascal Barneoud, Pia Delaere, Michel Perricaudet, Emmanuelle Vigne
  • Patent number: 6685934
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for basic blast growth factors (bFGF), preparation and uses thereof for the treatment and/or prevention of neurodegenerative diseases.
    Type: Grant
    Filed: October 9, 1996
    Date of Patent: February 3, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Jacques Mallet, Michel Perricaudet, Emmanuelle Vigne, Frédéric Revah, Marc Abitbol, Paul Roustan
  • Publication number: 20030143209
    Abstract: Modification of internal sites of the adenovirus fiber protein and hexon protein permit effective targeting of adenovirus vectors. Accessible sites to redirect adenovirus targeting were identified. The HVR5 loop of the hexon protein and the HI loop of the fiber protein (knob) were highly permissive for the insertion of foreign protein sequences, which apparently did not impact on the viability and productivity of corresponding viruses. Accessibility and functionality of the epitope strongly depend on the size of the neighboring spacers. Other results suggest that short targeting peptides can be effectively fused to the C-terminus of the fiber protein. In a specific embodiment, a series of adenovirus vectors modified at the HVR5 site, the fiber protein HI loop, or the fiber protein C-terminus to target urokinase-type plasminogen activator receptor bearing cells were prepared. Such vectors are particularly useful for targeting the vasculature, e.g. for gene therapy of cancers or cardiovascular conditions.
    Type: Application
    Filed: February 22, 2001
    Publication date: July 31, 2003
    Inventors: Emmanuelle Vigne, Jean-Francois Dedieu, Martine Latta, Patrice Yeh, Michel Perricaudet
  • Publication number: 20030096787
    Abstract: Novel adenovirus-derived viral vectors, the preparation thereof, and the use thereof in gene therapy, are disclosed.
    Type: Application
    Filed: November 21, 2002
    Publication date: May 22, 2003
    Inventors: Michel Perricaudet, Emmanuelle Vigne, Patrice Yeh
  • Publication number: 20030039634
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Application
    Filed: April 15, 2002
    Publication date: February 27, 2003
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cecile Orsini, Emmanuelle Vigne
  • Publication number: 20030022356
    Abstract: The invention concerns a method for producing recombinant virus. This method is based on the use of baculovirus for providing the complementary functions. It also concerns constructs used for implementing this method, the producing cells, and the resulting virus.
    Type: Application
    Filed: May 9, 2002
    Publication date: January 30, 2003
    Inventors: Helene Leblois-Prehaud, Michel Perricaudet, Emmanuelle Vigne, Patrice Yeh
  • Publication number: 20020098165
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Application
    Filed: December 19, 1997
    Publication date: July 25, 2002
    Applicant: Rhone-Poulenc S.A.
    Inventors: MICHEL PERRICAUDET, MARTINE LATTA, EDOUARD PROST, PATRICE YEH, CECILE ORSINI, EMMANUELLE VIGNE
  • Patent number: 6420170
    Abstract: A recombinant adenovirus in which the expression of a nucleic acid sequence coding for at least one homologous or heterologous gene of viral origin is placed under the control of an inducible promoter, is disclosed. The use of such recombinant adenoviruses for preparing AAVs, and a complementary cell line and preparation method therefor, are also disclosed. Furthermore, pharmaceutical compositions containing such an adenovirus are disclosed.
    Type: Grant
    Filed: December 19, 1997
    Date of Patent: July 16, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Michel Perricaudet, Martine Latta, Edouard Prost, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Patent number: 6410298
    Abstract: The invention concerns a method for reducing recombination phenomena among nucleic acids. It also concerns the use of said method for producing defective viruses not contaminated by replication particles. The invention further concerns novel viral constructs.
    Type: Grant
    Filed: September 11, 2000
    Date of Patent: June 25, 2002
    Assignee: Aventis Pharma S.A.
    Inventors: Joel Crouzet, Jean-Jacques Robert, Emmanuelle Vigne, Patrice Yeh
  • Patent number: 6387670
    Abstract: The invention concerns a method for producing recombinant virus. This method is based on the use of baculovirus for providing the complementary functions. It also concerns constructs used for implementing this method, the producing cells, and the resulting virus.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: May 14, 2002
    Assignee: Aventis Pharma, S.A.
    Inventors: Hélène Leblois-Prehaud, Michel Perricaudet, Emmanuelle Vigne, Patrice Yeh
  • Publication number: 20020031493
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic factor (GDNF), preparation thereof, and use thereof for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: August 1, 1997
    Publication date: March 14, 2002
    Applicant: RHONE-POULENC RORER S.A.
    Inventors: PHILIPPE HORELLOU, JACQUES MALLET, MICHEL PERRICAUDET, FREDERIC REVAH, EMMANUELLE VIGNE
  • Publication number: 20020028212
    Abstract: Recombinant viruses comprising a heterologous DNA sequence coding for a protein having glutamate decarboxylase (GAD) activity, preparation thereof, and therapeutic use thereof, in particular for treating and/or preventing degenerative neurological diseases.
    Type: Application
    Filed: November 5, 1996
    Publication date: March 7, 2002
    Inventors: MARIE-CLAUDE GEOFFROY, PHILIPPE HORELLOU, JEAN-FRANCOIS JULIEN, JACQUES MALLET, MICHEL PERRICAUDET, JEAN-JACQUES ROBERT, EMMANUELLE VIGNE, ALEXIS BEMELMANS
  • Patent number: 6294377
    Abstract: The present invention resides in use of a recombinant adenovirus of animal origin containing a heterologous DNA sequence for the preparation of a pharmaceutical composition intended for the therapeutic and/or surgical treatment of the human body.
    Type: Grant
    Filed: November 17, 1995
    Date of Patent: September 25, 2001
    Assignee: Rhone-Poulenc Rorer SA
    Inventors: Hedi Haddada, Bernard Klonjkowski, Michel Perricaudet, Emmanuelle Vigne
  • Patent number: 6261807
    Abstract: A novel method for preparing recombinant adenoviruses and the use of such adenoviruses in gene therapy are disclosed. Plasmids used in the construction of said adenoviruses are also disclosed.
    Type: Grant
    Filed: August 8, 1997
    Date of Patent: July 17, 2001
    Assignee: Rhone-Poulenc Rorer S.A.
    Inventors: Joël Crouzet, Laurent Naudin, Patrice Yeh, Cécile Orsini, Emmanuelle Vigne
  • Patent number: 6245330
    Abstract: Recombinant adenoviruses comprising a heterologous DNA sequence coding for glial-derived neurotrophic growth factor (GDNF) are provided. The recombinant adenoviruses are useful in a method of expressing GDNF in a cell, wherein the cell is present in a mammal suffering from Parkinson's disease, comprising infecting said cell with a replication-defective recombinant adenovirus comprising a DNA sequence encoding GDNF operably linked to a promoter by administering the adenovirus into cells of the central nervous system. The recombinant adenoviruses of the invention are also useful in a method of treating Parkinson's disease comprising administering into cells of the central nervous system of a mammal suffering therefrom a replication defective recombinant adenovirus comprising ITRs, an encapsidation sequence and a DNA sequence encoding GDNF operably linked to a promoter, wherein the adenovirus E1 gene is non-functional and GDNF is expressed at a level that provides a therapeutic effect.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: June 12, 2001
    Assignee: Aventis Pharma S.A.
    Inventors: Philippe Horellou, Jacques Mallet, Michel Perricaudet, Frédéric Revah, Emmanuelle Vigne
  • Patent number: RE38556
    Abstract: The present invention concerns defective recombinant adenoviruses containing an inserted gene encoding apolipoproteins, pharmaceutical compositions comprising the adenovirus, and their use for the treatment or prevention of pathologies linked to dyslipoproteinemias.
    Type: Grant
    Filed: August 4, 2000
    Date of Patent: July 13, 2004
    Assignee: Aventis Pharma S.A.
    Inventors: Patrick Benoit, Patrice Denefle, Michel Perricaudet, Sandrine Seguret, Emmanuelle Vigne